- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05229497
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
A Phase Ib/II Study of AK112#PD-1/VEGF Bispecific Antibody# in Combination With AK117#Anti-CD47 Antibody# in Advanced Malignant Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- Recruiting
- Zhejiang Cancer Hospital
-
Contact:
- Xiaozhong Chen, MD
- Phone Number: 13505717886
- Email: cxzfyun@sina.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 to 75 years old.
- Have a life expectancy of at least 3 months.
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Phase Ib: Histologically or cytologically confirmed selected advanced solid tumor.
Phase II:
Cohort 1 and 2 :
A. Has histologically confirmed recurrent or metastatic HNSCC who had failed only first-line platinum-containing therapy.
B. Has histologically confirmed recurrent or metastatic HNSCC with PD-L1 positive (CPS≥1) without prior systemic antitumor therapy.
Cohort 3: Has histologically confirmed recurrent or metastatic HNSCC without prior systemic antitumor therapy.
- Have at least one measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by investigator.
- Has adequate organ function.
Exclusion Criteria:
- Undergone major surgery within 30 days prior to the first dose of study treatment.
- Active central nervous system (CNS) metastases.
- History of active autoimmune disease that has required systemic treatment in the past 2 years (i.e.,corticosteroids or immunosuppressive drugs).
- Active Hepatitis B or Hepatitis C.
- Received previous immunotherapy, including immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy and other treatments targeting the mechanism of tumor immunity.
- History of severe bleeding tendency or coagulation disorder.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Phase Ib#Dosage regimen 1#
Subjects receive AK112 (20 mg/kg Q3W) + AK117 (30 mg/kg QW)
|
IV infusion,Specified dose on specified days
IV infusion,Specified dose on specified days
|
EXPERIMENTAL: Phase Ib#Dosage regimen 2#
Subjects receive AK112 (20 mg/kg Q3W) + AK117 (45 mg/kg QW)
|
IV infusion,Specified dose on specified days
IV infusion,Specified dose on specified days
|
EXPERIMENTAL: Phase II#Cohort 1#
Head and neck squamous cell carcinoma (HNSCC): AK112 (20 mg/kg Q3W)
|
IV infusion,Specified dose on specified days
|
EXPERIMENTAL: Phase II#Cohort 2#
HNSCC: AK112 (20 mg/kg Q3W) + AK117 (recommended Phase 2 dose)
|
IV infusion,Specified dose on specified days
IV infusion,Specified dose on specified days
|
EXPERIMENTAL: Phase II#Cohort 3#
HNSCC: AK112 (20 mg/kg Q3W) + AK117 (recommended Phase 2 dose)+Carboplatin/cisplatin+5-fluorouracil
|
IV infusion,Specified dose on specified days
IV infusion,Specified dose on specified days
IV infusion,Specified dose on specified days
IV infusion,Specified dose on specified days
IV infusion,Specified dose on specified days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with Adverse Events (AEs)
Time Frame: Up to approximately 2 years
|
Characterization of incidence, severity and abnormal clinically significant laboratory findings of AEs
|
Up to approximately 2 years
|
Objective Response Rate (ORR)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
|
Number of patients experiencing dose-limiting toxicities (DLTs)
Time Frame: During the first 3 weeks
|
During the first 3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival (OS)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Disease control rate (DCR)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Duration of Response (DOR)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Time to response (TTR)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Progression free survival (PFS)
Time Frame: Up to approximately 2 years
|
Up to approximately 2 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AK117-201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Malignant Tumors
-
Hangzhou Sumgen Biotech Co., Ltd.Recruiting
-
NovaRock Biotherapeutics, LtdRecruitingAdvanced Malignant TumorsChina
-
AkesoRecruiting
-
Nanjing Leads Biolabs Co.,LtdRecruitingAdvanced Malignant TumorsChina
-
CSPC Ouyi Pharmaceutical Co., Ltd.Not yet recruitingAdvanced Malignant TumorsChina
-
SUNHO(China)BioPharmaceutical CO., Ltd.RecruitingAdvanced Malignant TumorsChina
-
Nanjing Leads Biolabs Co.,LtdRecruitingAdvanced Malignant TumorsChina
-
Atridia Pty Ltd.Active, not recruitingAdvanced Malignant TumorsAustralia
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Enrolling by invitationAdvanced Malignant TumorsChina
-
AnewPharmaCompletedAdvanced Malignant Solid TumorsChina
Clinical Trials on AK112
-
AkesoTerminatedOvarian Neoplasms | Ovarian Cancer | Recurrent Ovarian Carcinoma | Relapsed Ovarian CancerChina
-
AkesoNot yet recruitingHepatocellular Carcinoma
-
AkesoNot yet recruiting
-
AkesoRecruiting
-
AkesoActive, not recruitingGynecologic Cancer | Ovarian Neoplasms | Endometrial Neoplasms | Cancer Metastatic | Cervical NeoplasmChina
-
AkesoRecruitingNon-small Cell Lung CancerChina
-
Akesobio Australia Pty LtdRecruitingNeoplasms MalignantAustralia
-
AkesoActive, not recruitingSolid Tumor, AdultChina
-
Harbin Medical UniversityNot yet recruitingHepatocellular CarcinomaChina